GlassScriptPhysician profile
Akash A Patel
NPI 1811955792
$1,830.16
in general payments reported to CMS, 2019-2025
14 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $25.68 · 2022: $22.46 · 2023: $106 · 2024: $722 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180 · Travel and Lodging: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.82 |
| Travel and Lodging | $490.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $691.85 | 2022-2025 | |
| Globus Medical, INC. | $490.00 | 2024-2025 | Xlif, Autobahn |
| Galderma Laboratories, L.P. | $158.06 | 2019-2025 | Nemluvio |
| Abbvie INC. | $144.64 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $84.12 | 2025 | |
| Allergan, INC. | $47.71 | 2019 | |
| Dermavant Sciences, INC. | $41.57 | 2024 | Vtama |
| Amgen INC. | $40.27 | 2025 | Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.65 | 2025 | Xifaxan |
| Leo Pharma INC. | $25.93 | 2025 | Adbry |
| Pfizer INC. | $21.46 | 2023 | |
| Arcutis Biotherapeutics, INC. | $19.67 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $14.95 | 2023 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.